COOPER COMPANIES, INC（COO）の決算・業績分析
COOPER COMPANIES, INCの2025年有価証券報告書をAI分析。売上高$4.1B(+5.1%)。営業利益$683M。Health Care。
目次
COOPER COMPANIES, INCの2025年度 業績サマリー
COOPER COMPANIES, INC（証券コード: COO）の2025年度決算・業績分析。売上高は$4.1B（前年比+5.1%）。営業利益は$683M（前年比-3.2%）。純利益は$375M（前年比-4.4%）。有価証券報告書を基に、業績変化の要因・リスク・見通し・セグメント構成を AI が分析しました。
COOPER COMPANIES, INCの2024年度 注目ポイント
※ 直近の2025年度XBRLデータは取込済みですが、AI分析は2024年度の10-Kを対象としています。
- Revenue grew 13.2% YoY to $3.3B (XBRL), driven by CooperVision's Toric/multifocal lenses (+11% YoY) and Sphere, other lenses (+5% YoY) (10-K).
- Net income fell 86.9% YoY to $386M (XBRL), despite a 64.7% gross margin (XBRL) and 15.3% operating margin (XBRL).
- Net debt rose to $2.4B (2.8x EBITDA) (XBRL), with $242M in CapEx (XBRL) and $78M in share repurchases (XBRL).
COOPER COMPANIES, INCの売上高変化の要因
- •Total revenue reached $3.3B (+13.2% YoY) (XBRL), with CooperVision's Toric/multifocal lenses contributing $1,257.2M (+11% YoY) and Sphere, other lenses contributing $1,352.2M (+5% YoY) (10-K). CooperSurgical revenue figures are not disclosed (XBRL). Growth was driven by demand for specialty eyecare products and fertility solutions.
COOPER COMPANIES, INCの営業利益変化の要因
- •Gross profit was $2.1B with a 64.7% margin (XBRL), while operating income rose 0.4% YoY to $508M (XBRL). Net income fell 86.9% YoY to $386M (XBRL), likely due to non-operating factors (10-K). Operating margin was 15.3% (XBRL), and net margin was 11.7% (XBRL).
COOPER COMPANIES, INCの事業リスクと対応
Recessionary pressures and economic volatility could harm liquidity and customer financial health (10-K).
Inflation may increase costs and limit pricing power (10-K).
International operations face currency risks, regulatory challenges, and geopolitical uncertainties (10-K).
Customer consolidation increases reliance on key accounts, risking revenue disruption (10-K).
Emerging market expansion faces regulatory barriers, distribution challenges, and customer acceptance issues (10-K).
COOPER COMPANIES, INCの今後の見通し・業績予想
COOPER COMPANIES, INCの事業内容
Cooper Companies, Inc. operates as a global medical device company with two segments: CooperVision (contact lenses) and CooperSurgical (fertility/women’s health products). Revenue is generated through the sale of contact lenses, surgical tools, IVF-related services, and contraception. Key customers include healthcare providers and patients, with no significant customer concentration (10-K). Competitive advantages include innovative products like FDA-approved MiSight 1 day lenses, global distribution networks, and strategic acquisitions (XBRL).
COOPER COMPANIES, INCのAI業績分析レポート（2024年度）
Highlights
Business Overview
Cooper Companies, Inc. operates as a global medical device company with two segments: CooperVision (contact lenses) and CooperSurgical (fertility/women’s health products). Revenue is generated through the sale of contact lenses, surgical tools, IVF-related services, and contraception. Key customers include healthcare providers and patients, with no significant customer concentration (10-K). Competitive advantages include innovative products like FDA-approved MiSight 1 day lenses, global distribution networks, and strategic acquisitions (XBRL).
Revenue Analysis
Total revenue reached $3.3B (+13.2% YoY) (XBRL), with CooperVision's Toric/multifocal lenses contributing $1,257.2M (+11% YoY) and Sphere, other lenses contributing $1,352.2M (+5% YoY) (10-K). CooperSurgical revenue figures are not disclosed (XBRL). Growth was driven by demand for specialty eyecare products and fertility solutions.
Profitability Analysis
Gross profit was $2.1B with a 64.7% margin (XBRL), while operating income rose 0.4% YoY to $508M (XBRL). Net income fell 86.9% YoY to $386M (XBRL), likely due to non-operating factors (10-K). Operating margin was 15.3% (XBRL), and net margin was 11.7% (XBRL).
Balance Sheet Analysis
Equity ratio was 65.7% (XBRL), with total equity at $7.6B (XBRL). Debt-to-equity ratio was 0.54x (XBRL), and net debt stood at $2.4B (2.8x EBITDA) (XBRL). Current ratio was 1.76x (XBRL), with $138M in cash (XBRL).
Cash Flow Analysis
Operating cash flow was $692M (XBRL), with $450M in free cash flow (FCF) after $242M in CapEx (XBRL). Financing activities included $3M in dividends and $78M in share repurchases (XBRL), totaling $81M returned to shareholders (XBRL).
Working Capital Analysis
Cash conversion cycle (CCC) was 215 days (XBRL), with receivables at 67 days, inventory at 230 days, and payables at 82 days (XBRL).
Risks
Outlook
Management expressed optimism about long-term market growth, particularly in contact lens technology (e.g., myopia management) (10-K), but highlighted risks from global economic conditions, inflation, and regulatory changes (10-K).
Health Careの企業一覧
COOPER COMPANIES, INCと同じ「Health Care」セクターの企業